The California STEM Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The California STEM Reporter.

Press releases published on June 11, 2026

Jun. 11, 2026

Quantum Cyber Entering Steady-State Scale Production, Launches Vertically Integrated Advanced Filament Manufacturing Division

Indeterminate GlobeNewswire

Jun. 11, 2026

Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Swarmer Publishes Letter From Its Chairman, Erik Prince, Outlining Strategy

Indeterminate GlobeNewswire

Jun. 11, 2026

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Indeterminate GlobeNewswire

Jun. 11, 2026

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Indeterminate GlobeNewswire

Jun. 11, 2026

Spinach® is the Number One Vape Brand in Canada

Indeterminate GlobeNewswire

Jun. 11, 2026

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Indeterminate GlobeNewswire

Jun. 11, 2026

Clinical Data Showed Average 67% Pain Score Reduction and 50% Gain in Walking Distance with Cartigenix HP® in 90 Days*†

Indeterminate GlobeNewswire

Jun. 11, 2026

Impact Analytics Honored as 2026 “Demand Forecasting Solution of the Year” for the Second Consecutive Year, by SupplyTech Breakthrough

Indeterminate GlobeNewswire

Jun. 11, 2026

BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Indeterminate GlobeNewswire

Jun. 11, 2026

Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline

Indeterminate GlobeNewswire

Jun. 11, 2026

Joveo Named Strategic Challenger on 2026 Fosway 9-Grid™ for Talent Acquisition

Indeterminate GlobeNewswire

Jun. 11, 2026

BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s Return

Indeterminate GlobeNewswire

Jun. 11, 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Indeterminate GlobeNewswire

Jun. 11, 2026

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Verano Completes 1-for-5 Reverse Stock Split, Advancing the Company’s Path Towards Prospective U.S. Stock Exchange Listing

Indeterminate GlobeNewswire

Jun. 11, 2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Indeterminate GlobeNewswire